Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
{{output}}
Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its application. Here, we genetically engineered healthy-donor-derived, CD19-targetin... ...
